The cell and gene therapy (CGT) patent landscape reveals a perhaps surprising leader: the German biopharmaceutical company, Immatics Biotechnologies GmbH. As GlobalData has noted, the firm is one of the top filers of patents for CAR-T cell-based therapies. This contrasts with the broader oncology patent space, where well-known Swiss companies like Novartis and Roche have…